PriceTargets.com logo

Daiichi Sankyo - DSNKY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$22.75 As of 12/4/2025 04:59 PM ET
▼ -0.1 (-0.44%)

This chart shows the closing price for DSNKY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daiichi Sankyo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSNKY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSNKY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Daiichi Sankyo in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $22.75.

This chart shows the closing price for DSNKY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Daiichi Sankyo. This rating changed within the last month from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2025Zacks ResearchDowngradeHold ➝ Strong Sell
6/6/2025Nomura SecuritiesUpgradeStrong-Buy
9/25/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
5/23/2023Sanford C. BernsteinInitiated CoverageUnderperform
8/14/2022Jefferies Financial GroupUpgradeHold ➝ Buy
3/8/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 5 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
11/4/2025
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Daiichi Sankyo logo
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $22.75
Low: $22.65
High: $23.02

50 Day Range

MA: $24.36
Low: $21.45
High: $27.37

52 Week Range

Now: $22.75
Low: $20.92
High: $31.72

Volume

198,364 shs

Average Volume

305,736 shs

Market Capitalization

$43.10 billion

P/E Ratio

21.46

Dividend Yield

0.63%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Daiichi Sankyo?

The following Wall Street analysts have issued research reports on Daiichi Sankyo in the last year: Nomura Securities, and Zacks Research.
View the latest analyst ratings for DSNKY.

What is the current price target for Daiichi Sankyo?

0 Wall Street analysts have set twelve-month price targets for Daiichi Sankyo in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Daiichi Sankyo in the next year.
View the latest price targets for DSNKY.

What is the current consensus analyst rating for Daiichi Sankyo?

Daiichi Sankyo currently has 1 sell rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DSNKY.

What other companies compete with Daiichi Sankyo?

Other companies that are similar to Daiichi Sankyo include Sanofi, GSK, argenex, Takeda Pharmaceutical and Insmed. Learn More about companies similar to Daiichi Sankyo.

How do I contact Daiichi Sankyo's investor relations team?

Daiichi Sankyo's physical mailing address is Daiichi Sankyo Bldg. A/B Kan, Chuo Ku, Tokyo To 103-8426. The company's listed phone number is (136) 225-1111 and its investor relations email address is [email protected]. The official website for Daiichi Sankyo is www.daiichisankyo.com. Learn More about contacing Daiichi Sankyo investor relations.